Nonstatin therapy obicetrapib promising for addressing unmet medical needs for high CV risk patients

Current guidelines for managing high-cardiovascular-risk patients include aggressive goals for low-density lipoprotein cholesterol (LDL-C). Nonstatin options have limitations and statin therapy alone is not sufficient to reach goals. Stephen J. Nicholls, Victorian Heart Institute, Monash University, Clayton, Victoria, Australia, and colleagues tested the lipid-lowering effects of the CETP inhibitor drug obicetrapib in a randomized, double-blind, placebo-controlled trial. The trial was conducted in dyslipidaemic patients (n = 120, median LDL-C 88 mg dl−1) with background high-intensity statin treatment.  

"The trial expanded the growing body of evidence to support the tolerability and safety of this specific CETP inhibitor," the researchers wrote. "Considering the unmet medical need for additional therapies for a substantial reduction in LDL-C in patients at high cardiovascular risk, the results from ROSE are promising."

"Additional phase 3 investigations including a cardiovascular outcomes trial are currently underway for further assessment of the safety and clinical benefits of obicetrapib," they concluded. 

Reference:

Nicholls, S.J., Ditmarsch, M., Kastelein, J.J. et al. Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial. Nat Med 28, 1672–1678 (2022). https://doi.org/10.1038/s41591-022-01936-7